HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.107.045526v1 49/2/255    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beer, A. J. Articles by Schwaiger, M. Search for Related Content PubMed PubMed Citation Articles by Beer, A. J. Articles by Schwaiger, M.

Patterns of _vβ₃ Expression in Primary and Metastatic Human Breast Cancer as Shown by ¹⁸F-Galacto-RGD PET

¹ Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; ² Department of Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; and ³ Department of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Correspondence: For correspondence or reprints contact: Ambros J. Beer, MD, Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany. E-mail: beer{at}roe.med.tum.de

The integrin _vβ₃ is a key player in angiogenesis and metastasis. Our aim was to study the uptake patterns of the _vβ₃-selective PET tracer ¹⁸F-galacto-RGD in invasive ductal breast cancer. Methods: Sixteen patients with primary (n = 12) or metastasized breast cancer (n = 4) were examined with ¹⁸F-galacto-RGD PET. Standardized uptake values (SUVs) were derived by region-of-interest analysis, and immunohistochemistry of _vβ₃ expression was performed (n = 5). Results: ¹⁸F-Galacto-RGD PET identified all invasive carcinomas, with SUVs from 1.4 to 8.7 (mean ± SD, 3.6 ± 1.8; tumor-to-blood and tumor-to-muscle ratios, 2.7 ± 1.6 and 6.2 ± 2.2, respectively). Lymph-node metastases were detected in 3 of 8 patients (mean SUV, 3.3 ± 0.8). SUVs in distant metastases were heterogeneous (2.9 ± 1.4). Immunohistochemistry confirmed _vβ₃ expression predominantly on microvessels (5/5) and, to a lesser extent, on tumor cells (3/5). Conclusion: Our results suggest generally elevated and highly variable _vβ₃ expression in human breast cancer lesions. Consequently, further imaging studies with ¹⁸F-galacto-RGD PET in breast cancer patients for assessment of angiogenesis or planning of _vβ₃-targeted therapies are promising.

Key Words: breast cancer • integrins • _vβ₃ • angiogenesis • PET • RGD

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				M. S. Morrison, S.-A. Ricketts, J. Barnett, A. Cuthbertson, J. Tessier, and S. R. Wedge Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy J. Nucl. Med., January 1, 2009; 50(1): 116 - 122. [Abstract] [Full Text] [PDF]

				A. R. Hsu and X. Chen Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis J. Nucl. Med., April 1, 2008; 49(4): 511 - 514. [Abstract] [Full Text] [PDF]